{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Personalized+Vaccine", "query": { "intervention": "Personalized Vaccine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Personalized+Vaccine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T19:30:29.857Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00689013", "title": "The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Herpes Zoster" ], "interventions": [ { "name": "Personalized letter", "type": "OTHER" }, { "name": "Flyer advertisement", "type": "OTHER" }, { "name": "Newspaper press release", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Tennessee", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 205, "start_date": "2008-02", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2009-04-23", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 3, "location_summary": "Johnson City, Tennessee • Manchester, Tennessee • Murfreesboro, Tennessee", "locations": [ { "city": "Johnson City", "state": "Tennessee" }, { "city": "Manchester", "state": "Tennessee" }, { "city": "Murfreesboro", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00689013" }, { "nct_id": "NCT04015700", "title": "Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics", "type": "BIOLOGICAL" }, { "name": "CELLECTRA®2000 EP Device supplied by Geneos Therapeutics", "type": "DEVICE" }, { "name": "Plasmid encoded IL-12", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-07-14", "completion_date": "2027-09-03", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04015700" }, { "nct_id": "NCT04930783", "title": "NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "CDX-301", "type": "DRUG" }, { "name": "NEOVAX", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-01-03", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04930783" }, { "nct_id": "NCT05743595", "title": "Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unmethylated Glioblastoma" ], "interventions": [ { "name": "Personalized Neoantigen DNA vaccine", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "TDS-IM v 2.0 electroporation device", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-10-27", "completion_date": "2029-03-09", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743595" }, { "nct_id": "NCT04397003", "title": "Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive-stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Neoantigen DNA vaccine", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "TDS-IM v2.0 Device", "type": "DEVICE" }, { "name": "Peripheral blood draws", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-03-30", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04397003" }, { "nct_id": "NCT05722652", "title": "A Multicomponent Clinic-based Intervention to Promote COVID-19 Vaccine Intention and Uptake Among Diverse Youth and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "COVID-19 Vaccination" ], "interventions": [ { "name": "CONFIDENCE", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 667, "start_date": "2023-03-27", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722652" }, { "nct_id": "NCT05141721", "title": "A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "GRT-C901", "type": "DRUG" }, { "name": "GRT-R902", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Fluoropyrimidine plus leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Project Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2022-02-12", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 43, "location_summary": "Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05141721" }, { "nct_id": "NCT02348320", "title": "Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Triple-Negative Breast Cancer", "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Personalized polyepitope DNA vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2015-06-17", "completion_date": "2020-03-12", "has_results": false, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02348320" }, { "nct_id": "NCT02510950", "title": "Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Astrocytoma, Grade IV" ], "interventions": [ { "name": "Personalized peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Poly-ICLC", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-12-03", "completion_date": "2017-02-14", "has_results": false, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02510950" }, { "nct_id": "NCT06324240", "title": "Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Early Stage Triple-Negative Breast Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vaccine Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2025-12-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-04T19:30:29.857Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06324240" } ] }